{"id":"W4401784358","doi":"10.1080/23995270.2024.2380247","title":"A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca; Omeros Corporation; Alexion Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008041783,0.002010684,0.004089033,0.001613097,0.0006484897,0.005202589,0.001888525,0.005825671,0.043394],"category_scores_gemma":[0.02944123,0.0007778699,0.00489301,0.002273002,0.0004831236,0.002408393,0.0006684673,0.006974709,0.01283815],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001776427,"about_ca_system_score_gemma":0.002671879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003010615,"about_ca_topic_score_gemma":0.003306253,"domain_scores_codex":[0.9953591,0.002336129,0.0008615481,0.0002774109,0.000863221,0.0003025141],"domain_scores_gemma":[0.9774233,0.01347915,0.00306857,0.0005280277,0.004173203,0.001327782],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005270952,0.00009701289,0.0002883977,0.01236777,0.0009044515,0.0001214772,0.00003400202,0.0002775142,0.0002674446,0.001052547,0.9282709,0.05104751],"study_design_scores_gemma":[0.02395626,0.003002457,0.006492895,0.02436221,0.00407042,0.0003971462,0.0000994983,0.0005455232,0.0005429188,0.004798911,0.9314984,0.0002333693],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.003409516,0.2682495,0.004176592,0.3647219,0.1913538,0.005574204,0.1012278,0.00107809,0.06020861],"genre_scores_gemma":[0.01737677,0.2107475,0.005213619,0.4446921,0.1940828,0.009238889,0.04831834,0.0006240227,0.0697061],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.043394,"threshold_uncertainty_score":0.1451674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005686959444619518,"score_gpt":0.2434480502845588,"score_spread":0.2377610908399392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}